Form 4: Immunome Director Philip Wagenheim Receives Stock Options

Director Philip Wagenheim was granted 9,897 stock options in Immunome, Inc. as part of standard equity compensation.

Summary

• Director Philip Wagenheim received a grant of 9,897 stock options for Immunome, Inc. (IMNM) common stock.
• The options have an exercise price of $18.16 per share.
• The grant was issued on June 10, 2026, with an expiration date of June 9, 2036.
• The options vest in four equal quarterly installments over one year, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the reporting person's continuous service with the company.

Future Outlook

The options vest in four equal quarterly installments starting June 10, 2026, through June 2027, assuming continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with company performance and long-term strategic goals.

Comparison to Industry Standards

• The use of quarterly vesting over one year for director compensation is consistent with standard corporate governance practices for mid-cap biotech firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of the first installment of options on September 10, 2026.

Key Dates

Keywords

Immunome, IMNM, Form 4, Insider Trading, Stock Options, Director Compensation